SCHEMBL6176734

SCHEMBL6176734

COC(=O)/C(=C/CC1CCCC1)c1ccc(-n2nnnc2C)c(C(F)(F)F)c1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMURF1 Q9HCE7 1/20 0.36
SCN9A Q15858 2/20 0.34
NOTUM Q6P988 1/20 0.34
LRRK2 Q5S007 2/20 0.34
ADCY8 P40145 1/20 0.33
ADCY1 Q08828 1/20 0.33
EPHX2 P34913 2/20 0.32
PDE4B Q07343 1/20 0.32
ROCK2 O75116 1/20 0.32
TAAR1 Q96RJ0 1/20 0.32
LMNA P02545 1/20 0.31
TAS1R3 Q7RTX0 1/20 0.31
TAS1R1 Q7RTX1 1/20 0.31
TAS1R2 Q8TE23 1/20 0.31
RBP4 P02753 1/20 0.31
TTR P02766 1/20 0.31
ATM Q13315 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6176744 1.00 SMURF1 (0.36) SMURF1SCN9ANOTUMLRRK2ADCY8
SCHEMBL6175131 0.90 NOTUM (0.35) SMURF1SCN9ANOTUMLRRK2ADCY8
SCHEMBL6175122 0.90 NOTUM (0.35) SMURF1SCN9ANOTUMLRRK2ADCY8
SCHEMBL2658917 0.88 SMURF1 (0.39) SMURF1SCN9ANOTUMLRRK2ADCY8
SCHEMBL2658911 0.88 SMURF1 (0.39) SMURF1SCN9ANOTUMLRRK2ADCY8
SCHEMBL2657964 0.83 GCK (0.38) EPHX2LMNA
SCHEMBL6175183 0.83 GCK (0.38) EPHX2LMNA
SCHEMBL6174191 0.80 NOTUM (0.38) SMURF1SCN9ANOTUMLRRK2ADCY8
SCHEMBL6174183 0.80 NOTUM (0.38) SMURF1SCN9ANOTUMLRRK2ADCY8
SCHEMBL2645445 0.76 CNR2 (0.38) EPHX2TAS1R3TAS1R1TAS1R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1311504-B1 TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2005-06-15 EP disclosed
US-6441180-B1 TO INCREASE INSULIN SECRETION, WHICH MAKES THEM USEFUL FOR TREATING TYPE II DIABETES HOFFMANN-LA ROCHE INC. 2002-08-27 US disclosed
US-20020065275-A1 Tetrazolyl-phenyl actamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-05-30 US disclosed
US-6388088-B1 ANTIDIABETIC AGENTS HOFFMAN-LA ROCHE INC. 2002-05-14 US disclosed
US-6369232-B1 ANTIDIABETIC AGENTS HOFFMANN-LA ROCHE INC. 2002-04-09 US disclosed
US-20020035267-A1 Tetrazolyl-phenyl acetamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-03-21 US disclosed
US-20020035266-A1 Tetrazolyl-phenyl acetamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035267-A1 Tetrazolyl-phenyl acetamide glucokinase activators GCKR, GCK, PCK1 SMURF1 4717/4885SCN9A 3237/4885NOTUM 1489/4885
US-20020035266-A1 Tetrazolyl-phenyl acetamide glucokinase activators GCKR, GCK, PCK1 SMURF1 4717/4885SCN9A 3237/4885NOTUM 1489/4885
US-20020065275-A1 Tetrazolyl-phenyl actamide glucokinase activators GCKR, GCK, PFKL SMURF1 4519/4885SCN9A 2804/4885NOTUM 1459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.